Cambridge Network

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel ...
Cambridge Network

Cambridge NeuroWorks drives UK neurotech forward with launch of nationwide Blue Sky Proof-of-Concept Fund

Cambridge NeuroWorks drives UK neurotech forward with launch of nationwide Blue Sky Proof-of-Concept Fund Cambridge ...
Cambridge Network

Beta Launch of LYEONS Heart

The Beta Launch of 23 LYEONS Heart devices is now live!
Cambridge Network

UK health: Focus on prevention can deliver £8 for each £1 invested

The UK has the potential to unlock £8 [1] in socio-economic returns for every £1 spent on preventive healthcare, according to ...